Cramer Urges Shift to AI Deployers, Highlights J&J’s AI Cancer Treatment Move
On Investopedia Express, Jim Cramer highlighted Johnson & Johnson’s recent use of artificial intelligence in cancer treatment development as a prime example of blue-chip firms deploying AI technologies. He advised investors to pivot from speculative AI builders to established companies like J&J for more sustainable growth.
1. Johnson & Johnson Sees Majority Buy Ratings and AI‐Led Oncology Push
Over the past month, 14 out of 20 Wall Street analysts covering Johnson & Johnson have raised their ratings to Buy or Strong Buy, up from 9 buys three months ago, according to a consensus report compiled on December 15, 2025. These upgrades have lifted the 12-month average price objective by 7.3%, to $172.40, implying double‐digit upside potential for investors. At the same time, J&J has earmarked $500 million for its new AI-driven oncology research initiative, which the company projects will contribute 5% incremental revenue growth by fiscal 2026. CNBC’s Jim Cramer has also highlighted J&J’s early clinical trials using machine learning algorithms to optimize dosing in its lung and breast cancer portfolios, calling the effort “a watershed moment” for the healthcare giant’s innovation roadmap. Investors will be watching J&J’s next quarterly update—scheduled for January 28—to see whether these analyst upgrades and AI investments translate into tangible margin expansion in the medical devices and pharmaceuticals segments.